Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in IgG/IgA MGUS
NCT07209371Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifaximin in monoclonal gammopathy of undetermined significance (MGUS) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Overall response rate at 90 days. Started Jan 2026; status: recruiting.
02
Drugs
rifaximin
03
Conditions
monoclonal gammopathy of undetermined significance (MGUS)
Beyond the preview
Go deeper on NCT07209371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209371.